Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of 14C-Napabucasin in Healthy Males
NCT03525405Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- May 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of napabucasin in solid tumor, sponsored by Sumitomo Pharma America. Primary endpoints: Pharmacokinetics for napabucasin and metabolites in plasma at 1 week, Pharmacokinetics for napabucasin and metabolites in urine up to 12 days and 1 more. Started May 2018; status: completed.
02
Drugs
napabucasin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03525405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03525405.